PROCEPT BioRobotics Corporation reported significant financial growth in its latest quarterly filing, with revenues reaching $79.2 million for the three months ended June 30, 2025, a 48% increase from $53.4 million in the same period last year. For the first half of 2025, the company generated $148.3 million in revenue, up 52% from $97.9 million in the first half of 2024. The increase in revenue was primarily driven by higher sales volumes of system sales, handpieces, and service contracts, particularly in the U.S. market, which accounted for approximately 88% of total revenue.
Despite the revenue growth, PROCEPT BioRobotics reported a net loss of $19.6 million for the second quarter of 2025, an improvement from a net loss of $25.6 million in the same quarter of 2024. For the six months ended June 30, 2025, the net loss was $44.3 million, compared to $51.6 million in the prior year. The company’s gross margin improved to 65% for both the second quarter and the first half of 2025, up from 59% and 58%, respectively, in the same periods of 2024, attributed to increased sales volume and better cost management.
In terms of operational developments, PROCEPT BioRobotics has expanded its install base of robotic systems, reaching a total of 762 units globally, including 595 in the U.S. The company has also received FDA clearance for its next-generation HYDROS Robotic System, which is expected to enhance its product offerings in the urology market. The company continues to focus on increasing system utilization and expanding its sales force to drive adoption of its Aquablation therapy, which is designed for the treatment of benign prostatic hyperplasia (BPH).
The company’s total operating expenses increased to $73.9 million in the second quarter of 2025, up from $58.3 million in the same quarter of 2024, primarily due to higher selling, general, and administrative expenses as PROCEPT invests in its commercial infrastructure. As of June 30, 2025, the company had cash and cash equivalents of $302.7 million, down from $333.7 million at the end of 2024, reflecting ongoing investments in growth and operations.
Looking ahead, PROCEPT BioRobotics anticipates continued revenue growth driven by increased adoption of its robotic systems and the expansion of its market presence. The company plans to leverage its strong clinical evidence and relationships with key opinion leaders in urology to enhance market acceptance of its products. However, the company also acknowledges the need for ongoing investment in research and development to support future innovations and maintain competitive advantages in the rapidly evolving surgical robotics market.
About PROCEPT BioRobotics Corp
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.